Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02178163 · ClinicalTrials.gov registry record · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
A NA study of Stage IV Non-small Cell Lung Cancer and Recurrent Non-small Cell Lung Cancer, sponsored by Barbara Ann Karmanos Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 1,020
- Enrollment target
- 11
- Study locations
NCT02178163 is a NA study of Stage IV Non-small Cell Lung Cancer and Recurrent Non-small Cell Lung Cancer that is actively recruiting participants, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 1,020 participants, above the 645-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (58% higher). The trial reports 11 study locations across 1 state.
The verdict
NCT02178163, a NA study of Stage IV Non-small Cell Lung Cancer and Recurrent Non-small Cell Lung Cancer, is actively recruiting participants, sponsored by Barbara Ann Karmanos Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,020 participants
- Enrollment target
- 11
- Study locations
Study Summary
This research trial studies comprehensive genomic analysis in tissue samples from patients with non-small cell lung cancer that has come back or is stage IV. Comprehensive genomic analysis may identify specific gene mutations (changes in deoxyribonucleic acid \[DNA\]) and help doctors to tailor treatment to target the specific mutations.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER cytology specimen collection procedure
Study Locations (11)
Michigan
- KCI at McLaren Bay Region - Bay City
- KCI at Mclaren Bloomfield Hills - Bloomfield Hills
- KCI At McLaren Clarkston - Clarkston
- Barbara Ann Karmanos Cancer Institute - Detroit
- KCI at McLaren Flint - Flint
- KCI at McLaren Greater Lansing, Mid Michigan Physicians - Lansing
- KCI at McLaren Lapeer Region - Lapeer
- KCI at McLaren Macomb - Mount Clemens
- KCI at McLaren Central Michigan - Mount Pleasant
- KCI at Northern Michigan - Petoskey
- KCI at McLaren Port Huron - Port Huron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,020 participants |
| Start Date | 2014-08-01 |
| Est. Completion | 2027-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02178163
The ClinicalTrials.gov registry entry for NCT02178163 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,020 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 645-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (58% higher). The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stage IV Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT02178163 reports 11 study locations spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT02178163 about?
NCT02178163 is a clinical study titled "Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer". This research trial studies comprehensive genomic analysis in tissue samples from patients with non-small cell lung cancer that has come back or is stage IV. Comprehensive genomic analysis may identify specific gene mutations (changes in deoxyribonucleic acid \[DNA\]) and help doctors to tailor trea...
What is the current status of trial NCT02178163?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,020 participants. The study started on 2014-08-01. Estimated completion is 2027-07.
What conditions does trial NCT02178163 study?
This clinical trial studies the following conditions: Stage IV Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT02178163?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cytology specimen collection procedure (OTHER).
Who is sponsoring clinical trial NCT02178163?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02178163 being conducted?
This trial has 11 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Patient-centered, Optimal Integration of Survivorship and Palliative Care
RECRUITING · NA
-
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
RECRUITING · NA
-
Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
COMPLETED · NA
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
ACTIVE NOT RECRUITING · Phase 1
-
Ruxolitinib for Cancer Cachexia
ACTIVE NOT RECRUITING · Early Phase 1
Explore more on PlainTrial
Stage IV Non-small Cell Lung Cancer
All registered trials for this condition
Recurrent Non-small Cell Lung Cancer
All registered trials for this condition
Michigan
All trials with a study site in Michigan
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.